Compare Amgen, Inc. (AMGN) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs GoPro Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while GoPro Inc trades at $0.76 (market cap $131.96M). The key difference: Amgen, Inc. is far larger — about 1486.2× GoPro Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| AMGN | GPRO | |
|---|---|---|
Market Cap | $196.12B | $131.96M |
Sector | Health | Technology |
52-Week High | $388.16 | $2.88 |
52-Week Low | $271.18 | $0.64 |
Enterprise Value | $241.41B | $179.91M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GoPro (GPRO) trades at $0.76, up 0.37% with neutral technical signals. The company faces severe financial distress with negative net income margins (-20.7%) and ROE (-236.05%), though valuation ratios appear low (P/E 4.56, P/S 0.2). Recent strategic review for potential sale and CEO's $20M financing provide near-term catalysts, but consecutive earnings misses and declining revenue ($652M in 2025) highlight operational challenges.
Outlook remains highly speculative with binary outcomes. The strategic sale process offers potential upside, but ongoing cash burn, negative equity, and competitive pressures present substantial downside risk. Analyst sentiment is mixed with 21% buy ratings, reflecting the company's precarious financial position and event-driven investment thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
